510 related articles for article (PubMed ID: 28156002)
1. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
Nguyen HM; Vessella RL; Morrissey C; Brown LG; Coleman IM; Higano CS; Mostaghel EA; Zhang X; True LD; Lam HM; Roudier M; Lange PH; Nelson PS; Corey E
Prostate; 2017 May; 77(6):654-671. PubMed ID: 28156002
[TBL] [Abstract][Full Text] [Related]
2. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
[TBL] [Abstract][Full Text] [Related]
3. Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells.
Porter LH; Hashimoto K; Lawrence MG; Pezaro C; Clouston D; Wang H; Papargiris M; Thorne H; Li J; ; Ryan A; Norden S; Moon D; Bolton DM; Sengupta S; Frydenberg M; Murphy DG; Risbridger GP; Taylor RA
BJU Int; 2018 Jun; 121(6):971-978. PubMed ID: 28977728
[TBL] [Abstract][Full Text] [Related]
4. Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling.
Van Hemelryk A; Tomljanovic I; de Ridder CMA; Stuurman DC; Teubel WJ; Erkens-Schulze S; Verhoef EI; Remmers S; Mahes AJ; van Leenders GJLH; van Royen ME; van de Werken HJG; Grudniewska M; Jenster GW; van Weerden WM
Cells; 2022 Nov; 11(22):. PubMed ID: 36429059
[TBL] [Abstract][Full Text] [Related]
5. An original patient-derived xenograft of prostate cancer with cyst formation.
Yoshikawa T; Kobori G; Goto T; Akamatsu S; Terada N; Kobayashi T; Tanaka Y; Jung G; Kamba T; Ogawa O; Inoue T
Prostate; 2016 Aug; 76(11):994-1003. PubMed ID: 27098584
[TBL] [Abstract][Full Text] [Related]
6. Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts.
Lam HM; McMullin R; Nguyen HM; Coleman I; Gormley M; Gulati R; Brown LG; Holt SK; Li W; Ricci DS; Verstraeten K; Thomas S; Mostaghel EA; Nelson PS; Vessella RL; Corey E
Clin Cancer Res; 2017 May; 23(9):2301-2312. PubMed ID: 27993966
[No Abstract] [Full Text] [Related]
7. Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer.
Valta MP; Zhao H; Saar M; Tuomela J; Nolley R; Linxweiler J; Sandholm J; Lehtimäki J; Härkönen P; Coleman I; Nelson PS; Corey E; Peehl DM
Clin Exp Metastasis; 2016 Apr; 33(4):325-37. PubMed ID: 26873136
[TBL] [Abstract][Full Text] [Related]
8. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.
Palanisamy N; Yang J; Shepherd PDA; Li-Ning-Tapia EM; Labanca E; Manyam GC; Ravoori MK; Kundra V; Araujo JC; Efstathiou E; Pisters LL; Wan X; Wang X; Vazquez ES; Aparicio AM; Carskadon SL; Tomlins SA; Kunju LP; Chinnaiyan AM; Broom BM; Logothetis CJ; Troncoso P; Navone NM
Clin Cancer Res; 2020 Sep; 26(18):4933-4946. PubMed ID: 32576626
[TBL] [Abstract][Full Text] [Related]
9. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of patient-derived xenografts for hormone-naïve and castrate-resistant prostate cancers to improve treatment modality evaluation.
Wu P; Xu R; Chen X; Zhao Y; Tan D; Zhao Y; Qin W; Zhang C; Ge X; Shi C
Aging (Albany NY); 2020 Feb; 12(4):3848-3861. PubMed ID: 32092044
[TBL] [Abstract][Full Text] [Related]
11. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
12. Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.
Sychev ZE; Day A; Bergom HE; Larson G; Ali A; Ludwig M; Boytim E; Coleman I; Corey E; Plymate SR; Nelson PS; Hwang JH; Drake JM
Mol Cancer Res; 2024 May; 22(5):452-464. PubMed ID: 38345532
[TBL] [Abstract][Full Text] [Related]
13. A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.
Beshiri ML; Tice CM; Tran C; Nguyen HM; Sowalsky AG; Agarwal S; Jansson KH; Yang Q; McGowen KM; Yin J; Alilin AN; Karzai FH; Dahut WL; Corey E; Kelly K
Clin Cancer Res; 2018 Sep; 24(17):4332-4345. PubMed ID: 29748182
[No Abstract] [Full Text] [Related]
14. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
[TBL] [Abstract][Full Text] [Related]
15. Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.
Philp LK
Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.
Winters B; Brown L; Coleman I; Nguyen H; Minas TZ; Kollath L; Vasioukhin V; Nelson P; Corey E; Üren A; Morrissey C
Anticancer Res; 2017 Jul; 37(7):3385-3396. PubMed ID: 28668826
[TBL] [Abstract][Full Text] [Related]
17. Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Wong N; Major P; Kapoor A; Wei F; Yan J; Aziz T; Zheng M; Jayasekera D; Cutz JC; Chow MJ; Tang D
Oncotarget; 2016 Dec; 7(50):83115-83133. PubMed ID: 27825118
[TBL] [Abstract][Full Text] [Related]
18. SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.
Zhang X; Coleman IM; Brown LG; True LD; Kollath L; Lucas JM; Lam HM; Dumpit R; Corey E; Chéry L; Lakely B; Higano CS; Montgomery B; Roudier M; Lange PH; Nelson PS; Vessella RL; Morrissey C
Clin Cancer Res; 2015 Oct; 21(20):4698-708. PubMed ID: 26071481
[TBL] [Abstract][Full Text] [Related]
19. Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance.
Lam HM; Nguyen HM; Corey E
Methods Mol Biol; 2018; 1786():1-27. PubMed ID: 29786784
[TBL] [Abstract][Full Text] [Related]
20. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]